ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
admin 18th May 2017 Uncategorised 0Investors are champing at the bit for data that will help them determine how Eli Lilly’s candidate abemaciclib stacks up against its in-class rivals—particularly Pfizer’s fast-growing Ibrance—in the efficacy department. But analysts say they’ll have to keep waiting.
More: ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
Source: fierce